It has been almost two months since my last blog here on PharmaNewsAnalysis.com and there are some legitimate reasons for it. However, the main reason is that there is so much happening in our industry that I have been swamped with work and travel (By no means, I am complaining...). However, I am overwhelmed by your attention, requests for constant blogs and continued interest in this blog. Thank you all for subscribing and passing this blog to your colleagues, friends and peers in the industry. I do hope that I will be more regular here. With that behind me, allow me to share with some key takeaways from the last 2 months. The following are based on many assignments that we are involved in:
- More Divestments: Expect more Pharma Companies to divest their old or small products as well as plants in the US and EU.
- More M&A Activity: Expect more Indian/Chinese companies to acquire in the US, EU and also within India
- More Layoffs: Expect more job cuts and layoffs
- More Cost-Cutting: We are already seeing a hugfe way of cost cutting measures being put in place at all of our clients... from limits on travel to conference attendance to raises, etc.
- Bigger Outsourcing Deals: We have never seen more urgency from our clients to outsource and leverage external resources than the last 2-3 months.
- Newer Generic Pharma Business Models: Newer and nimble Generic Pharma companies (virtual, etc.) are joining hands with larger companies to compete with bigger Generics... Business models are out of box and lots of money is being raised...
- Hillary/Obama/McCain: Most pharma executives are worried about the outcome from the Presidential elections....
So, where does that leave us? I would welcome comments...
By the way, I am in the process of launching a new company - it is still in stealth mode... but if you have interest, please drop me an email and I may just let you peek in...
